bioRxiv is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.
COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
Vascular and Endovascular Research Network, , Benson, R. A., Bosanquet, D. C., Nandhra, S., Shalhoub, J., Saratzis, A., Forsythe, R., Onida, S., Dovell, G., Hitchman, L., Dattani, N., Preece, R., Ambler, G. K., Imray, C.
Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M. M., Leung, S.-Y. J., Morne, J., Greene, D., Holtgrave, D. R., Hoefer, D., Kumar, J., Udo, T., Hutton, B., Zucker, H. A.
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).